에이프릴바이오

397030KOSDAQ자연과학 및 공학 연구개발업

56.5 / 100

Reference Date: 2026-04-13

Financial Score18.5 / 40

News Sentiment20.0 / 25

Momentum8.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but PBR raises overvaluation concerns. Plunged 20.7% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

April Bio is a research and development-focused company established in 2013, leveraging human antibody production and protein half-life extension technologies to develop antibody therapeutics and sustained recombinant protein drugs. Utilizing its core HuDVFab library and SAFA platform technologies, the company focuses on developing treatments for autoimmune and inflammatory diseases, generating revenue through global licensing agreements with pharmaceutical companies under its RIPCO business model.

Number of Employees

27people

Average Salary

201.1M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 120.074.0Point

PBR

13.31Industry Average 3.820.0Point

3.5x industry avg (risky)

ROE

-10.39Industry Average -32.113.5Point

Well below industry avg

Debt Ratio

0.27Industry Average 7.528.0Point

Half of industry avg (excellent)

Trend 2023~20253.0 / 10 points

Revenue Growth Rate

0.0 / 3

Avg ▼92.1% (1-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲41.5% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -1.9% (improving, 3yr)

Detailed News Sentiment

3 totalPositive 2Neutral 1Negative 0Average Sentiment Score 80

Positive
K-바이오, 한국투자공사 우군 확보…"성장 마중물 수혜주는?"
한국투자공사(KIC)가 국내 바이오 기업의 글로벌 시장 진출을 지원하기 위해 1억5000만달러를 투자할 계획으로, 에이프릴바이오와 같은 K-바이오 기업에 긍정적인 영향을 미칠 것으로 예상된다.
Positive
美아포지, 아토피藥 앞세워 주가 급등…에이프릴바이오 주목받는 이유
미국 아포지테라퓨틱스의 아토피 피부염 치료제 임상 2상 결과가 긍정적으로 나오면서, 에이프릴바이오가 기술수출한 아토피 피부염 치료제 'APB-R3'의 무결막염 안전성 강점이 재차 주목받고 있다.
Neutral
코스피 거래대금 위축에도 코스닥은 활기…삼천당제약 27%↑
이달 코스닥 시장의 거래대금이 증가했으며 특히 바이오주를 중심으로 거래대금 증가세가 두드러졌으나, 에이프릴바이오에 대한 직접적인 언급은 없다.

Detailed Momentum

52-week position6.0Point

52w upper range (69%)

Current 54,900Won52-week high 73,00052-week low 13,610

1-month return0.0Point

1m -20.66% (strong drop)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

2 totalPositive 0Neutral 2Negative 0

Neutral주식등의대량보유상황보고서(약식)2026-04-09
Neutral정기주주총회결과2026-03-25